Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06501963 · ClinicalTrials.gov registry record · Phase 4
Revealing Protective Immunity to Influenza Using Systems Immunology
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT06501963: Completed Phase 4 study, sponsored by Emory University.
NCT06501963 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 51 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06501963, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
The goals of this study are to better understand the human immune response to influenza vaccines, specifically the live attenuated (weakened) influenza vaccine given as a nasal spray. Better understanding why this vaccine does not work as well in adults as it does in children may help design better influenza vaccines.
Primary Outcome
The immunogenicity of the live attenuated influenza vaccine (LAIV) is evaluated by the quantification of antibody titers using hemagglutination inhibition (HAI) assays. HAI titers are used as markers of part of the immune response to influenza and may vary by influenza strain.
Interventions
- BIOLOGICAL Live Attenuated Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2025-04-01 |
| Phase | Phase 4 |
What the finished NCT06501963 record still lists
NCT06501963 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Live Attenuated Influenza Vaccine is the first listed.
NCT06501963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06501963 about?
NCT06501963 is a clinical study titled "Revealing Protective Immunity to Influenza Using Systems Immunology". The goals of this study are to better understand the human immune response to influenza vaccines, specifically the live attenuated (weakened) influenza vaccine given as a nasal spray. Better understanding why this vaccine does not work as well in adults as it does in children may help design better ...
What is the current status of trial NCT06501963?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2024-10-14. Estimated completion is 2025-04-01.
What interventions are being tested in trial NCT06501963?
The interventions under investigation include: Live Attenuated Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06501963?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06501963's enrollment target sits among peer trials
51 1249th of 2000 higher than 746 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI